These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 22426080)

  • 1. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease.
    Barabino S; Chen Y; Chauhan S; Dana R
    Prog Retin Eye Res; 2012 May; 31(3):271-85. PubMed ID: 22426080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.
    Periman LM; Perez VL; Saban DR; Lin MC; Neri P
    J Ocul Pharmacol Ther; 2020 Apr; 36(3):137-146. PubMed ID: 32175799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands.
    Stern ME; Beuerman RW; Fox RI; Gao J; Mircheff AK; Pflugfelder SC
    Cornea; 1998 Nov; 17(6):584-9. PubMed ID: 9820935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye.
    Nagelhout TJ; Gamache DA; Roberts L; Brady MT; Yanni JM
    J Ocul Pharmacol Ther; 2005 Apr; 21(2):139-48. PubMed ID: 15857280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate and Adaptive Cell Populations Driving Inflammation in Dry Eye Disease.
    Reyes JL; Vannan DT; Eksteen B; Avelar IJ; Rodríguez T; González MI; Mendoza AV
    Mediators Inflamm; 2018; 2018():2532314. PubMed ID: 30158831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease.
    Ratay ML; Glowacki AJ; Balmert SC; Acharya AP; Polat J; Andrews LP; Fedorchak MV; Schuman JS; Vignali DAA; Little SR
    J Control Release; 2017 Jul; 258():208-217. PubMed ID: 28501670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage.
    Xia Y; Zhang Y; Du Y; Wang Z; Cheng L; Du Z
    J Nanobiotechnology; 2024 May; 22(1):233. PubMed ID: 38725011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.
    Barabino S; Benitez-Del-Castillo JM; Fuchsluger T; Labetoulle M; Malachkova N; Meloni M; Utheim TP; Rolando M
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8642-8652. PubMed ID: 32964952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRI Microspheres prevent key signs of dry eye disease in a murine, inflammatory model.
    Ratay ML; Balmert SC; Acharya AP; Greene AC; Meyyappan T; Little SR
    Sci Rep; 2017 Dec; 7(1):17527. PubMed ID: 29235530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A new approach for better comprehension of diseases of the ocular surface].
    Baudouin C
    J Fr Ophtalmol; 2007 Mar; 30(3):239-46. PubMed ID: 17417148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease.
    Ratay ML; Balmert SC; Bassin EJ; Little SR
    Acta Biomater; 2018 Apr; 71():261-270. PubMed ID: 29526828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the lacrimal functional unit in the pathophysiology of dry eye.
    Stern ME; Gao J; Siemasko KF; Beuerman RW; Pflugfelder SC
    Exp Eye Res; 2004 Mar; 78(3):409-16. PubMed ID: 15106920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry eye as a mucosal autoimmune disease.
    Stern ME; Schaumburg CS; Pflugfelder SC
    Int Rev Immunol; 2013 Feb; 32(1):19-41. PubMed ID: 23360156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravital Multiphoton Microscopy of the Ocular Surface: Alterations in Conventional Dendritic Cell Morphology and Kinetics in Dry Eye Disease.
    Jamali A; Seyed-Razavi Y; Chao C; Ortiz G; Kenyon B; Blanco T; Harris DL; Hamrah P
    Front Immunol; 2020; 11():742. PubMed ID: 32457740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal tolerance disruption favors disease progression in an extraorbital lacrimal gland excision model of murine dry eye.
    Guzmán M; Keitelman I; Sabbione F; Trevani AS; Giordano MN; Galletti JG
    Exp Eye Res; 2016 Oct; 151():19-22. PubMed ID: 27443502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic inhibitors for the treatment of dry eye syndrome.
    Rodríguez-Pomar C; Pintor J; Colligris B; Carracedo G
    Expert Opin Pharmacother; 2017 Dec; 18(17):1855-1865. PubMed ID: 29115899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The core mechanism of dry eye disease is inflammation.
    Wei Y; Asbell PA
    Eye Contact Lens; 2014 Jul; 40(4):248-56. PubMed ID: 25390549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-related Defects in Ocular and Nasal Mucosal Immune System and the Immunopathology of Dry Eye Disease.
    Farid M; Agrawal A; Fremgen D; Tao J; Chuyi H; Nesburn AB; BenMohamed L
    Ocul Immunol Inflamm; 2016 Jun; 24(3):327-47. PubMed ID: 25535823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FTY720 ameliorates Dry Eye Disease in NOD mice: Involvement of leukocytes inhibition and goblet cells regeneration in ocular surface tissue.
    Xiao W; Xu GT; Zhang J; Zhang J; Zhang Y; Ye W
    Exp Eye Res; 2015 Sep; 138():145-52. PubMed ID: 26187517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for anti-inflammatory therapy in dry eye syndrome.
    de Paiva CS; Pflugfelder SC
    Arq Bras Oftalmol; 2008; 71(6 Suppl):89-95. PubMed ID: 19274418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.